Variety of eligible patients: CDEC discussed the uncertainty in the number of patients with reasonably extreme to extreme hemophilia B in Canada eligible for etranacogene dezaparvovec. Scientific experts consulted by CADTH indicated that some individuals who will be labeled as possessing mild or average disorder may have a extreme bleeding https://hemgenix27159.aioblogs.com/88639853/not-known-factual-statements-about-hemgenix